On November 17, 2026 CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, reported the achievement of a preclinical milestone for one of the lead programs in its collaboration with Regeneron, triggering a $5 million milestone payment.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Regeneron and CytomX collaboration agreement combines CytomX’s PROBODY therapeutic masking technology with Regeneron’s Veloci-Bi bispecific antibody platform to develop bispecifics that remain inactive within systemic circulation until activated by proteases highly enriched in the tumor microenvironment. This approach has the potential to broaden the therapeutic window and minimize off-target side effects for next-generation T-cell engaging therapies.
"Achievement of this first milestone from our Regeneron partnership represents the translation of promising science towards the clinic and underscores the potential synergistic approach of combining our respective technologies. Following the expansion of our collaboration in June 2026, we are excited to advance our aligned vision of bringing highly innovative new treatment options to cancer patients," said Sean McCarthy, D. Phil, CEO and Chairman of CytomX.
(Press release, CytomX Therapeutics, NOV 17, 2026, View Source [SID1234674898])